A new study has found the right dosage to administer a highly effective HIV treatment to newborns who are at risk of getting HIV.
Dolutegravir is one of the most effective and safest HIV medicines, and the preferred drug treatment recommended by the World Health Organization. It has been in use for more than a decade as an HIV treatment by millions of adults and adolescents living with HIV in over 100 countries. But there’s no specific drug formulation for newborns.
While many pregnant women have been taking dolutegravir for years to prevent mother-to-child transmission of HIV, this is not the case for everyone.
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Jenny Lei Ravelo@JennyLeiRavelo
Jenny Lei Ravelo is a Devex Senior Reporter based in Manila. She covers global health, with a particular focus on the World Health Organization, and other development and humanitarian aid trends in Asia Pacific. Prior to Devex, she wrote for ABS-CBN, one of the largest broadcasting networks in the Philippines, and was a copy editor for various international scientific journals. She received her journalism degree from the University of Santo Tomas.
